Uses of anti-bcma chimeric antigen receptors
AssigneeCelgene Corporation
InventorsKristen HEGE, Payal PATEL, Steven NOVICK, Lars STERNAS
Life of this patent
Estimating the term…
Abstract
The invention provides uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.
Claims25
A method of depleting BCMA-expressing cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed to B Cell Maturation Antigen (BCMA), wherein the immune cells are administered in a dosage of from 150×106 cells to 450×106 cells, and wherein before said administration said subject has received one or more lines of prior therapy comprising one or more of:
- a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, an anti-CD38 antibody, panobinostat, and elotuzumab.
A method of treating a disease caused by BCMA-expressing cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed to B Cell Maturation Antigen (BCMA), wherein the immune cells are administered in a dosage of from 150×106 cells to 450×106 cells, and wherein before said administration said subject has received one or more lines of prior therapy comprising one or more of a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, an anti-CD38 antibody, panobinostat, and elotuzumab.
A method of treating a cancer that expresses BCMA in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed to B Cell Maturation Antigen (BCMA), wherein the immune cells are administered in a dosage of from 150×106 cells to 450×106 cells, and wherein before said administration said subject has received one or more lines of prior therapy comprising one or more of a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, an anti-CD38 antibody, panobinostat, and elotuzumab.
Dependencies are inferred from the claim text.